Clostridium Botulinum Market was worth USD xx billion in 2018 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2023. Botulism is a disease which causes paralysis and is caused by the bacteria Clostridium botulinum. Some symptoms include weakness, paralysis, vision and swallowing, breathing and speaking problems. The weakness further leads to fatigue of limb muscles. The symptoms are not caused by the bacterium itself, but by the toxin produced by the bacterium.
The major factors that drives growth of botulism market includes, lack of cleanliness in certain regions of the world and increase in the awareness about disease and treatments, increase in R&D practices and availability of efficient solutions for botulism. In addition, owing to strong efforts by WHO and CDC, the disease is getting irradiated slowly. However, high cost of research and development projects and government austerity are some of the hurdles expected to hinder the growth of botulism market.
The market for Clostridium Botulinum is broadly categorized into product, end user and distribution channel. By product the market is classified into botulinum toxin type A and botulinum toxin type B. By end user the market is divided into aesthetic and therapeutics. The aesthetic segment accounted for a major share of the market. By distribution channel the market is segmented into hospitals, clinics and retail pharmacies.On the basis of geography, the market is analysed under various regions namely North America, Europe, Asia-Pacific and Rest of the World. The Clostridium Botulinum market was dominated by North America followed by Europe. Asia Pacific is considered to be a lucrative market is expected to grow at a high CAGR.
Some of the top players operating in clostridium botulinum infections market are XOMA Ltd., AlphaVax, Inc., Cangene Corporation, Morphotek, Inc., DynPort Vaccine Company LLC, Emergent BioSolutions, Inc., Molecular Targeting Technologies, Inc. and many others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Botulinum toxin type A
5.1.3 Botulinum toxin type B
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Aesthetic
5.2.3 Therapeutics
5.2.4 Y-o-Y Growth Analysis, By application
5.2.5 Market Attractiveness Analysis, By application
5.2.6 Market Share Analysis, By application
5.3 Distribution channel
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Retail pharmacies
5.3.5 Y-o-Y Growth Analysis, By distribution channel
5.3.6 Market Attractiveness Analysis, By distribution channel
5.3.7 Market Share Analysis, By distribution channel
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By application
6.1.3.4 By distribution channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By application
6.1.4.4 By distribution channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By application
6.1.5.4 By distribution channel
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 DynPort Vaccine Company
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Emergent BioSolutions, Inc.
8.3 XOMA Ltd.
8.4 AlphaVax
8.5 Cangene Corporation
8.6 Morphotek, Inc.
8.7 Morphotek, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
